AVELOX Drug Patent Profile

When do Avelox patents expire, and when can generic versions of Avelox launch?

Avelox is a drug marketed by Bayer Hlthcare and is included in two NDAs.

The generic ingredient in AVELOX is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Avelox

A generic version of AVELOX was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18^th, 2014.

Summary for AVELOX

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	82
Patent Applications:	5,010
Drug Prices:	Drug price information for AVELOX
What excipients (inactive ingredients) are in AVELOX?	AVELOX excipients list
DailyMed Link:	AVELOX at DailyMed

See drug prices for AVELOX

See drug sales revenues for AVELOX

Recent Clinical Trials for AVELOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Daiichi Sankyo, Inc.	Phase 4
Usona Institute	Phase 1
University of Karachi	Phase 1

See all AVELOX clinical trials

US Patents and Regulatory Information for AVELOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999		DISCN	Yes	No
Bayer Hlthcare	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER	moxifloxacin hydrochloride	SOLUTION;INTRAVENOUS	021277-001	Nov 30, 2001		DISCN	Yes	No

Expired US Patents for AVELOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999

International Patents for AVELOX

See the table below for patents covering AVELOX around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	745282
Canada	1340114	DERIVES D'ACIDE 7-(1-PYRROLIDINYL)-3-QUINOLONE ET NAPHTYRIDONECARBOXYLIQUE; METHODE DE PREPARATION ET DERIVES DE SUBSTITUTION MONO- ET BICYCLIQUE PYRRODILINE EN TANT QUE PRODUITS INTERMEDIAIRE POUR LA PREPARATION, ETAGENTS ANTIBACTERIENTS ET ADDITIFS D'ALIMENTATION COMPRENANT LES DERIVES (7-(1-PYRROLIDINYL)-3-QUINOLONE-AND -NAPHTHYRIDONE-CARBOXYLICACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND SUBSTITUTED MONO-AND BICYCLIC PYRROLIDINE DERIVATIVES AS INTERMEDIATE PRODUCTS FOR THEIR PREPARATION, AND ANTIBACTERIAL AND FEED ADDITIVES CONTAINING THEM)
Philippines	26723	7-(1-pyrrolidinyl)-3-quinolone and naphthyridone carboxylic acid derivatives as antibacterial agents and feed additives
Norway	168889
European Patent Office	1128831
New Zealand	229914	HETEROCYCLICALLY-SUBSTITUTED QUINOLONE OR NAPHTHYRIDONE CARBOXYLIC ACIDS; INTERMEDIATES, PHARMACEUTICALS AND FEED ADDITIVES
Peru	13042000

Supplementary Protection Certificates for AVELOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0350733	11/2000	Austria		PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
0350733	C300111	Netherlands		PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621
0350733	300111	Netherlands
0780390	PA2004012	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
0350733	2001C/030	Belgium		PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621
0780390	PA2004012,C0780390	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309
0350733	SPC/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313

AVELOX Market Analysis and Financial Projection Experimental

Moxifloxacin HCL Market Dynamics and Financial Trajectory: A Comprehensive Analysis

Introduction to Moxifloxacin HCL

Moxifloxacin HCL, commonly known by the brand name AVELOX, is a broad-spectrum antibiotic used to treat various bacterial infections. This drug is widely recognized for its effectiveness against respiratory, skin, and intra-abdominal infections.

Market Segmentation

The Moxifloxacin HCL market is segmented based on several key factors:

• Product Type: The market is segmented into qualified grade, first grade, and excellence grade[1].
• Dosage Form: Moxifloxacin HCL is available in oral, parenteral, and ophthalmic forms[1].
• Application: It is used to treat conditions such as bronchitis, pneumonia, sinusitis, pelvic inflammatory disease, and others[1].

Market Dynamics

Drivers

The growth of the Moxifloxacin HCL market is driven by several factors:

• Rising Prevalence of Bacterial Infections: The increasing cases of respiratory infections, urinary tract infections, and pneumonia are significant drivers. These infections necessitate the use of potent antibiotics like Moxifloxacin HCL[1][3].
• Low Cost of Medication: Compared to other antibiotics, Moxifloxacin HCL is relatively cost-effective, which fuels its market growth[1].
• Advancements in Pharmaceutical Research: Innovations in drug formulations, including new delivery mechanisms like intravenous and ophthalmic solutions, are making Moxifloxacin HCL more accessible and effective[3].

Restraints

Despite the growth drivers, there are several restraints affecting the market:

• Side Effects: Moxifloxacin HCL is associated with side effects such as abdominal discomfort, diarrhea, vomiting, nausea, and mouth sores, which can deter some patients[1].
• High Cost of Treatment for Certain Conditions: The high cost of treatment for conditions like Small Bowel Syndrome (SBS) can restrain market growth[1].

Financial Trajectory

Market Size and Growth

The Moxifloxacin HCL market is projected to grow significantly over the forecast period. As of 2023, the market was valued at approximately USD 472.26 million and is expected to reach USD 499.93 million in 2024. By 2032, the market is projected to grow to USD 788.46 million, reflecting a compound annual growth rate (CAGR) of 5.86% from 2024 to 2032[3].

Regional Analysis

• North America: This region is a leading market for Moxifloxacin HCL, driven by the high prevalence of bacterial infections and advanced healthcare infrastructure. The United States dominates this market due to its robust pharmaceutical industry and high R&D investments in antibiotics[3].
• Europe and Asia-Pacific: These regions also show significant growth, with Europe characterized by high prescription rates and substantial research investments, while Asia-Pacific is focusing on expanding healthcare infrastructure and improving access to essential medicines[3][4].

Impact of COVID-19

The COVID-19 pandemic has had a mixed impact on the Moxifloxacin HCL market. While the pandemic led to increased demand for antibacterial treatments due to the rise in secondary bacterial infections, it also disrupted global supply chains and manufacturing processes. This resulted in delays in product deliveries and affected sales in the short term[1].

Market Opportunities

The Moxifloxacin HCL market presents several opportunities for growth:

• Expanding Healthcare Infrastructure: In developing regions such as Asia-Pacific, Africa, and Latin America, governments are investing heavily in healthcare facilities and pharmaceutical access. This expansion is expected to increase the demand for effective treatments like Moxifloxacin HCL[3].
• Regulatory Policies and Accessibility: Regulatory policies and the accessibility of healthcare services in different regions are key factors influencing the market. Developed regions are characterized by high prescription rates and significant research investments, while emerging markets are focusing on improving access to essential medicines[3][4].

Competitive Landscape

The Moxifloxacin HCL market is competitive, with several key players:

• Bayer: The original developer of Moxifloxacin HCL.
• Rivopharm: Known for its high-quality pharmaceutical products.
• Actavis UK: A significant player in the generic pharmaceutical market.
• MERCK: A major pharmaceutical company with a wide range of products.
• Other Players: Companies like Cayman, Allergan, Tecoland, BOC Sciences, Aurobindo, and NIVIKA Chemo Pharma also play important roles in the market[4].

PEST and SWOT Analysis

A comprehensive PEST (Political, Economic, Social, and Technological) and SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis is crucial for understanding the market dynamics. These analyses help in evaluating factors such as political stability, economic conditions, social trends, and technological advancements that affect the market. Additionally, they highlight the strengths and weaknesses of key players and identify opportunities and threats in the market[1][4].

Key Takeaways

• The Moxifloxacin HCL market is expected to grow at a CAGR of 5.86% from 2024 to 2032.
• The market is driven by the rising prevalence of bacterial infections and advancements in pharmaceutical research.
• North America is a leading market due to its advanced healthcare infrastructure and high R&D investments.
• Emerging markets in Asia-Pacific, Africa, and Latin America offer significant growth opportunities.
• The market faces restraints such as side effects and high treatment costs for certain conditions.

FAQs

What is the projected market size of Moxifloxacin HCL by 2032?

The Moxifloxacin HCL market is projected to reach USD 788.46 million by 2032[3].

What are the primary drivers of the Moxifloxacin HCL market?

The primary drivers include the rising prevalence of bacterial infections and the low cost of medication compared to other antibiotics[1][3].

Which region dominates the Moxifloxacin HCL market?

North America, particularly the United States, dominates the market due to its advanced healthcare infrastructure and high R&D investments in antibiotics[3].

What are the common side effects associated with Moxifloxacin HCL?

Common side effects include abdominal discomfort, diarrhea, vomiting, nausea, and mouth sores[1].

How has the COVID-19 pandemic impacted the Moxifloxacin HCL market?

The pandemic has disrupted supply chains and manufacturing processes but also increased demand for antibacterial treatments due to secondary bacterial infections[1].

Cited Sources

1. The Insight Partners: Moxifloxacin HCL Market Key Players Analysis 2031
2. GlobeNewswire: Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
3. Global Growth Insights: Moxifloxacin HCl Market Size and Growth Analysis | CAGR of 5.86%
4. Cognitive Market Research: Moxifloxacin HCl Market Report 2024 (Global Edition)